Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MariGen Shield is a medical device developed by Kerecis for the management of chronic and complex wounds, such as diabetic foot ulcers and pressure ulcers. It consists of a fenestrated, intact fish skin graft derived from sustainably sourced Icelandic fish, integrated with a silicone contact layer. The fish skin serves as a biocompatible scaffold containing natural components like fat, protein, elastin, and glycans, which support cell growth and tissue regeneration. The silicone layer facilitates application and protects the wound bed. It is processed using the proprietary EnviroIntact method and is classified as a medical device under FDA 510(k) clearance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MariGen Shield.